Detalhe da pesquisa
1.
XPO1-mutant NSCLC without STK11/KEAP1 mutations may predict better survival to immunotherapy.
J Transl Med
; 19(1): 421, 2021 10 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34627293
2.
Construction of a B cell-related gene pairs signature for predicting prognosis and immunotherapeutic response in non-small cell lung cancer.
Front Immunol
; 13: 989968, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36389757
3.
Interferon Regulatory Factor 4 Correlated With Immune Cells Infiltration Could Predict Prognosis for Patients With Lung Adenocarcinoma.
Front Oncol
; 11: 698465, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34195096
4.
Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy.
Lung Cancer
; 151: 39-43, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33296806
5.
BIM Deletion Polymorphism Confers Resistance to Osimertinib in EGFR T790M Lung Cancer: a Case Report and Literature Review.
Target Oncol
; 13(4): 517-523, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29907952
6.
NF1-Mutant Cancer and Immune Checkpoint Inhibitors: A Large Database Analysis.
Clin Lung Cancer
; 22(5): 480-481, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33895104
7.
NSCLC patients with MET non-exon-14 mutations rather than MET exon 14 mutations response to immune checkpoint inhibitors.
Lung Cancer
; 152: 202-204, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33422364
8.
MET-mutant cancer and immune checkpoint inhibitors: A large database analysis.
Lung Cancer
; 150: 256-258, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33012556
9.
ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis.
Lung Cancer
; 150: 252-253, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32800612